FDAapproval95% confidence
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (ophthalmology) as Mankind Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Supporting Context
- Therapeutic area
- Ophthalmology · Glaucoma
- Sub-indication
- Ophthalmology
Related signal: FDA Approves Brimonidine Tartrate Application ANDA220398 by Mankind Pharma